/ricerca/ansait/search.shtml?tag=
Show less

Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

From FVG and ICGEB aid to develop biosimilar drugs in Serbia

From FVG and ICGEB aid to develop biosimilar drugs in Serbia

A cooperation project kicks off for new expertise.

UDINE, 15 gennaio 2024, 22:25

Redazione ANSA

ANSACheck

- RIPRODUZIONE RISERVATA

Developing skills to produce biosimilar drugs in Serbia, as well as consolidating the cooperation relationship of the Friuli Venezia Giulia Region with that territory. These are the goals of the MabTher project, the launch of which was formalized today by Regional Labor Councillor Alessia Rosolen and ICGEB Director General Lawrence Banks.
    The initiative involves transferring knowledge from ICGEB to the Serbian Institute for the Application of Nuclear Energy to develop and produce the Mab biosimilar drug Trastuzumab, a monoclonal antibody used to treat breast and stomach cancer.
    Serbian researchers and officials, the FVG Region informs, will be supported in acquiring the necessary skills for technology transfer and training in the Biotechnology development unit of Icgeb. Technology transfer will be supervised by ICGEB staff, who will assist Serbian researchers in replicating the process of making Trastuzumab in Serbia using local facilities and industries. Banks remarked that building local manufacturing capacity and skills is a cornerstone for creating local employment, wealth, and stability.
    This pilot initiative involves the transfer of technologies that ICGEB has developed over many years of optimization so that biotherapeutics that meet all Food and Drug Administration (FDA) and European Pharmacopoeia standards can be transferred to the Serbian industry. These products can then be produced and marketed locally at a lower price than standard international supply chains, thus making health care more affordable and creating jobs at the same time. "Sharing the knowledge and production techniques of these drugs with other nations of our territorial area, such as the Balkans - Rosolen said - makes it possible to overcome the inequalities produced by the pharmaceutical market and produces positive effects, strengthening international cooperation and collaboration."
   

ALL RIGHTS RESERVED © Copyright ANSA

Not to be missed

Condividi

Or use

ANSA Corporate

If it is news,
it is an ANSA.

We have been collecting, publishing and distributing journalistic information since 1945 with offices in Italy and around the world. Learn more about our services.